Chronic Obstructive Pulmonary Disease
Conditions
Interventions
Intervantion Participants use Aerobika twice daily for 10min before long acting bronchodilator inhalation. Treatment time is 4 weeks.
Control Participants continue long acting bronchodilator inhalat
Sponsors
Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subject has post-long acting bronchodilator forced expiratory volume in first second (FEV1) <= 80% predicted. Subject has respiratory symptoms >= 10 on the CAT total score, and has the phlegm symptoms >= 2 on the CAT phlegm score. Subject has declared that he/she has stopped smoking for at least 8 weeks prior to entering the study Subject has read, understood, and signed the informed consent form.
Exclusion criteria
Exclusion criteria: The condition that the investigator judges to exclude from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in FEV1 before and after 4-week treatment with Aerobika. | — |
Secondary
| Measure | Time frame |
|---|---|
| Following parameters will be assessed for before and at 4-week 4-week treatment with Aerobika. 1. VC, FVC, V50, and V25 2. IOS(R5, R5ins, R5exp, R20, X5, X5ins, X5exp, Fres, Ax) 3. 6 minute-walking test 4. CAT score, mMRC 5. Acute exacerbation | — |
Countries
Japan
Contacts
Public ContactMasamichi Mineshita
St. Marianna University School of Medicine Division of Respiratory Medicine, Department of Internal Medicine
Outcome results
None listed